This overview shares key insights from our report on Phase I–III clinical trials that initiated in 2022 across all therapeutic areas, as well as in-depth analyses into the key diseases, players, and geographies that impact the pharmaceutical industry. In 2022, the roller coaster resumed as the healthcare industry continued to be influenced by the global economy and political climate.
